The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 12, 2024

Filed:

Jun. 23, 2023
Applicants:

Hanall Biopharma Co., Ltd., Daejeon, KR;

Immunovant Sciences Gmbh, Basel, CH;

Inventors:

William Louis Macias, Indianapolis, IN (US);

Su Liang, Briarcliff Manor, NY (US);

Hyeakyung Ahn, Gyeonggi-do, KR;

Haeyoung Yong, Gyeonggi-do, KR;

Mijin Jung, Gyeonggi-do, KR;

Minho Yoon, Gyeonggi-do, KR;

Eunsun Kim, Seoul, KR;

Seungkook Park, Seoul, KR;

Hyeeun Shim, Seoul, KR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/283 (2013.01); A61P 37/06 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure relates to an anti-FcRn antibody or an antigen binding fragment thereof with improved stability and uses thereof. The anti-FcRn antibody or antigen binding fragment thereof binds to FcRn non-competitively with IgG and the like compared to the parent antibody, HL161AN, thereby having improved stability, such as reducing the production rate of aggregates while maintaining the biological activity of significantly reducing the amount of pathogenic autoantibodies in the blood. Therefore, it may be utilized more efficiently for the treatment of an autoimmune disease.


Find Patent Forward Citations

Loading…